Quick Answer
Aurinia Pharmaceuticals Inc. reported Diluted EPS of $2.07 per share for fiscal year 2025.
Aurinia Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.07 | +5075.0% |
| 2024 | $0.04 | +107.4% |
| 2023 | -$0.54 | +28.9% |
| 2022 | -$0.76 | +45.7% |
| 2021 | -$1.40 | -60.9% |
| 2020 | -$0.87 | +8.4% |
| 2019 | -$0.95 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.23 | +130.0% | +43.8% |
| June 30, 2025 | $0.16 | +1500.0% | +0.0% |
| March 31, 2025 | $0.16 | +328.6% | +60.0% |
| September 30, 2024 | $0.10 | +211.1% | +900.0% |
| June 30, 2024 | $0.01 | +112.5% | +114.3% |
| March 31, 2024 | -$0.07 | +61.1% | +22.2% |
| September 30, 2023 | -$0.09 | -50.0% | -12.5% |
| June 30, 2023 | -$0.08 | +68.0% | +55.6% |
- Aurinia Pharmaceuticals Inc. showed an increase of +5075.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Aurinia Pharmaceuticals Inc.’s diluted eps has grown by 317.9% (from $0.95 per share (loss) to $2.07 per share).
- The most recent figure is from Aurinia Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: